Search research articles
Contact Us
Filters
Showing results (21-30 of 38) with videos related to
Page
of 4
Sort By:
The Journal of Clinical Psychiatry
|
December 4, 2024
Long-Term Safety, Tolerability, and Durability of Treatment Effect of Olanzapine and Samidorphan: Results of a 4-Year Open-Label Study
Jacob S Ballon, René S Kahn, Christina Arevalo, et al.
The Journal of Clinical Psychiatry
|
March 7, 2020
Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study
Steven G Potkin, Jelena Kunovac, Bernard L Silverman, et al.
European Journal of Case Reports in Internal Medicine
|
April 13, 2023
A Patient with a Brain Abscess Presenting as an Acute Stroke
Thomas Matthews, Cathy Keegan, David McDonnell, et al.
Clinical Therapeutics
|
November 5, 2013
Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia
Malcolm Mitchell, Prajakti Kothare, Richard Bergstrom, et al.
Innovations in Clinical Neuroscience
|
August 24, 2019
Olanzapine Plus Samidorphan in Subjects with Schizophrenia and Comorbid Alcohol Use Disorder: Rationale and Design for a Phase II, Double-blind, Randomized Study
Leslie Citrome, Stephanie S O'Malley, David McDonnell, et al.
The American Journal of Psychiatry
|
December 17, 2009
Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia
John M Kane, Holland C Detke, Dieter Naber, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
April 20, 2007
D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia
David Mamo, Shitij Kapur, Matcheri Keshavan, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|
February 1, 2020
Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study
Lei Sun, Sergey Yagoda, Hongqi Xue, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
February 2, 2008
Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program
Jeonghoon Ahn, Jeffrey S McCombs, Changun Jung, et al.
The Journal of Clinical Psychiatry
|
March 22, 2023
Olanzapine/Samidorphan in Young Adults With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder Who Are Early in Their Illness: Results of the Randomized, Controlled ENLIGHTEN-Early Study
René S Kahn, John M Kane, Christoph U Correll, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 38) with videos related to
Sort By:
Page
of 4
The Journal of Clinical Psychiatry
|
December 4, 2024
Long-Term Safety, Tolerability, and Durability of Treatment Effect of Olanzapine and Samidorphan: Results of a 4-Year Open-Label Study
Jacob S Ballon, René S Kahn, Christina Arevalo, et al.
The Journal of Clinical Psychiatry
|
March 7, 2020
Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study
Steven G Potkin, Jelena Kunovac, Bernard L Silverman, et al.
European Journal of Case Reports in Internal Medicine
|
April 13, 2023
A Patient with a Brain Abscess Presenting as an Acute Stroke
Thomas Matthews, Cathy Keegan, David McDonnell, et al.
Clinical Therapeutics
|
November 5, 2013
Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia
Malcolm Mitchell, Prajakti Kothare, Richard Bergstrom, et al.
Innovations in Clinical Neuroscience
|
August 24, 2019
Olanzapine Plus Samidorphan in Subjects with Schizophrenia and Comorbid Alcohol Use Disorder: Rationale and Design for a Phase II, Double-blind, Randomized Study
Leslie Citrome, Stephanie S O'Malley, David McDonnell, et al.
The American Journal of Psychiatry
|
December 17, 2009
Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia
John M Kane, Holland C Detke, Dieter Naber, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
April 20, 2007
D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia
David Mamo, Shitij Kapur, Matcheri Keshavan, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|
February 1, 2020
Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study
Lei Sun, Sergey Yagoda, Hongqi Xue, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
February 2, 2008
Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program
Jeonghoon Ahn, Jeffrey S McCombs, Changun Jung, et al.
The Journal of Clinical Psychiatry
|
March 22, 2023
Olanzapine/Samidorphan in Young Adults With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder Who Are Early in Their Illness: Results of the Randomized, Controlled ENLIGHTEN-Early Study
René S Kahn, John M Kane, Christoph U Correll, et al.
Page
of 4